Direct Healthcare Professional Communication (DHPC) on propofol: risk of sepsis with multiple withdrawals from one container
2023.05.16
Active substance: propofol
In agreement with the Federal Institute for Drugs and Medical Devices (BfArM), the marketing authorisation holders of medicinal products containing propofol inform that medicinal products containing propofol are only authorised for single use in a single patient. Propofol must be removed from a container under aseptic conditions. Non-compliance with the recommendations for use can lead to sepsis with a life-threatening or fatal outcome.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN